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From today’s perspective, it is obvious that macroautophagy (hereafter autophagy) is an important pathway that is connected to
a range of developmental and physiological processes. This viewpoint, however, is relatively recent, coinciding with the molecular
identiﬁcation of autophagy-related (Atg) components that function as the protein machinery that drives the dynamic membrane
eventsofautophagy.Itmaybediﬃcult,especiallyforscientistsnewtothisareaofresearch,toappreciatethattheﬁeldofautophagy
long existed as a “backwater” topic that attracted little interest or attention. Paralleling the development of the autophagy ﬁeld was
the identiﬁcation and analysis of the cytoplasm-to-vacuole targeting (Cvt) pathway, the only characterized biosynthetic route that
utilizes the Atg proteins. Here, we relate some of the initial history, including some never-before-revealed facts, of the analysis of
the Cvt pathway and the convergence of those studies with autophagy.
1. The Background
To understand the origin of the studies that led to the
identiﬁcation of the Cvt pathway, we need to brieﬂy step
back into the early days of yeast molecular genetics. Randy
Schekman’s group was studying the secretory pathway and
isolating mutants defective in various steps including endo-
p l a s m i cr e t i c u l u m( E R ) - t o - G o l g it r a n s p o r ta sw e l la ss e c r e -
tion to the cell surface. Two former postdocs from the
Schekman lab, Scott Emr and Tom Stevens, decided to
pursue a similar direction, but to avoid a direct overlap with
Randy Schekman by focusing on a pathway that branches
oﬀ from the secretory pathway, the delivery of proteins to
the vacuole. The Emr and Stevens labs isolated a new set of
mutants initially named vpt (vacuolar protein targeting) [1]
and vpl (vacuolar protein localization) [2], and subsequently
vps (vacuolar protein sorting), which are defective in the
delivery of resident proteins to the vacuole. Being interested
in protein sorting, one of us (D.J.K.) went to Scott Emr’s lab
to learn about yeast.
While in the Emr lab, I characterized the vacuolar
delivery of proteinase A (Pep4) and vacuolar alkaline phos-
phatase (Pho8). Around that time, the sequence of the gene
encoding another vacuolar hydrolase, aminopeptidase I
(Ape1) was published [3, 4]. It is important to keep in mind
that this was the late 1980s, quite some time before the Sac-
charomyces cerevisiae genome was sequenced in its entirety.
In fact, automated sequencing was relatively new, so it was
still a major accomplishment when a gene was sequenced.
Until then, only the sequences of Pep4 [5, 6], Prc1 (car-
boxypeptidase Y) [7], Pho8 [8], Prb1 (proteinase B) [9],
and Ams1 (α-mannosidase) [10] were known among the
vacuolar hydrolases. Thus, it was quite exciting to those of
us studying vacuolar protein targeting when a new protein
sequence became available. One of my main goals in the
Emr lab was to identify the vacuolar-targeting motif and
determine a consensus sequence (mapping consensus target-
ingorretentionsignalswasverypopularinthosedays),atask
that was all the more diﬃcult due to the limited number of
proteins available for comparison. Hence, I was particularly
interested in having a new protein that I could analyze.
Ape1 was known to be a vacuolar hydrolase, and it
was characterized as being a glycoprotein [11]. The latter
ﬁnding ﬁt with the fact that all of the characterized vacuolar
hydrolases traﬃc through the secretory pathway to the Golgi
complex and from there are diverted to the vacuole. One2 International Journal of Cell Biology
interesting feature of the protein sequence for the precursor
form of Ape1 (prApe1), however, was that it lacked a stan-
dard signal sequence. Accordingly, I assumed that it entered
the ER by a unique mechanism. This seemed to add some
additional interest to the analysis, as the idea of analyzing yet
one more vacuolar hydrolase was getting somewhat tedious.
When I discussed the idea of analyzing the targeting of
prApe1 with Scott Emr, however, he was not interested. After
all, even if the details of the process were slightly unusual,
we were still talking about the characterization of another
vacuolar hydrolase that transits through a portion of the
secretory pathway. Indeed, at the time, there seemed to be
more interesting projects to pursue, so the analysis of prApe1
was left on the “back burner”.
Shortly after that time, I started an independent position
at the University of California, Davis. To stay clear of the
Emr lab (which, for a new assistant professor, loomed like
an 800-pound gorilla), I pursued an analysis of the vacuolar
H+-translocating ATPase and vacuolar acid trehalase. At that
time, Scott forwarded to me a letter (this was just before
email became widely used) from a postdoc applicant that
he was not able to invite to his lab. That postdoc, Nieves
Garcia Alvarez, was from one of the labs, that of Paz
Suarez-Rendueles,whichwasinvolvedincharacterizingyeast
vacuolar hydrolases, and I agreed to oﬀer her a position.
Nieves initially worked on the vacuolar ATPase project. I
knew, however, that her lab in Spain was one of two that had
essentially simultaneously sequenced the APE1/LAP4 gene
encoding prApe1 [4]. During Nieves’ time in my lab, I wrote
to Beth Jones who had published one paper on Ape1 [12]
and asked if she intended to pursue this topic; I did not
want to compete with her, but she indicated that she was not
going to be working on it, and I was welcome to it. Thus, I
obtained the gene from the Suarez-Rendueles lab and a new
postdoc from that lab, Rosaria Cueva Noval, along with my
postdocDebbieYaverandme,begantoexaminethevacuolar
targeting of prApe1.
The initial experiments on prApe1 were confusing,
because I could not ﬁnd any evidence for glycosylation or
for the existence of the protein within the compartments of
the secretory pathway [13]. (As a side note, our ﬁrst paper on
Ape1 was published back-to-back with the ﬁrst paper from
Yoshinori Ohsumi’s lab on the characterization of autophagy
in yeast [14]. This was coincidental, and, to be honest, I
paid no attention to the Ohsumi paper at that time, because
it was on the topic of autophagy; I was studying protein
targeting, not some presumed “garbage” pathway that was
only used for protein degradation.) Eventually, it dawned on
me that the published data were incorrect and that Ape1
was not a glycoprotein. At this time, Fred Dice was making
headlines with his analysis of the KFERQ—(KFERQ being
the consensus sequence for the recognized substrates) or
pentapeptide-dependent pathway for the transport of pro-
teins into the lysosome (the current name for this pathway,
“chaperone-mediated autophagy,” had not been coined yet)
[15]. Considering that Ape1 was not a glycoprotein, and
that it did not enter the endoplasmic reticulum, I reasoned
that it entered the vacuole by translocating directly across
the limiting membrane. Accordingly, I further assumed that
theremustbeproteinmachinery,similartotheasyetunchar-
acterizedcomponentsinvolvedintheKFERQpathway,inthe
vacuolar membrane just waiting for me to come along and
identify them.
Therefore, in order to identify the vacuolar membrane
translocation components, we generated a chimera of
prApe1 fused to the HIS3 gene. Our initial screen was based
on the idea that a his3 mutant strain of yeast would not be
able to grow in the absence of histidine if the chimera was
eﬃciently delivered to the vacuole. Accordingly, we could
isolate mutants that were able to grow without histidine, and
they would have defects in the various components of the
translocation machinery. It became clear early on that the
screen was not working, although we did not know why;
we could not easily follow the localization of the chimera
because the green ﬂuorescent protein was not yet being
used for cell biology studies. Randy Schekman was giving
a seminar on campus at that time, and I told him about
our project. He suggested that we generate antibodies that
only recognized prApe1 and carry out a screen looking for
mutants that accumulate the precursor form of the protein.
We did attempt that approach, using colony blots after trans-
ferring cells to nitrocellulose, but it was very diﬃcult to score
positive colonies. However, we also noticed that wild-type
cells analyzed by western blot, when grown appropriately,
had essentially no prApe1; all of the protein was in the
mature form. We also determined (using a pep4Δ mutant
as the control) that we could easily detect the precursor that
accumulated when one out of ten colonies was defective
for prApe1 maturation. Accordingly, even though it was
laborious, Tanya Harding, and later Ann Hefner-Gravink, in
my lab began to analyze random mutants in batches of ten
for the accumulation of prApe1.
Weisolatedaseriesofsuchmutantsandplacedtheminto
complementation groups [16]. This was quite exciting as we
were ﬁnally about to identify the long-awaited translocation
machinery for the vacuole. To be sure that we were not
going to waste our time analyzing mutants that were already
known, we began to compare our mutants with all other
previously identiﬁed mutants that aﬀected vacuolar protein
delivery. Of course this included the vps mutants from Tom
StevensandScottEmr,butalsoendocytosismutantsandvac-
uolar morphology (vam) mutants. Even though we did not
expect overlaps from the latter, we wanted to be thorough.
In fact, we were so careful that we even requested protein
extracts from Yoshinori Ohsumi and Michael Thumm, who
had isolated apg [17]a n daut [18] mutants, respectively, that
are defective in autophagy. Obviously (or so we thought at
thetime),therewasnotgoingtobeanoverlap;autophagyisa
degradativepathway,andourmutants(thennamedcvt)were
defective in a biosynthetic pathway. Imagine our surprise,
and disappointment, when we found an essentially complete
overlap among these three sets of genes [19, 20]. The
disappointment was for two reasons. First, instead of having
a unique set of mutants that we could study on our own,
we knew we immediately had competitors. Second, we were
being dragged against our will into the ﬁeld of autophagy.
Nonetheless, we continued with our studies of prApe1
targeting and began to clone the CVT/APG/AUT genes andInternational Journal of Cell Biology 3
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Figure 1: Overview of the Cvt pathway. (1) Formation of the Cvt complex: Precursor Ape1 forms a dodecamer. Multiple dodecamers
assemble into an Ape1 complex. The Ape1 complex binds Atg19 via the prApe1 propeptide to form the Cvt complex. Other Cvt cargo,
including Ams1 and Ape4, bind Atg19 at distinct domains. (2) Movement to the PAS: Atg19 binds the scaﬀold protein Atg11, and the Cvt
complex moves to the PAS. (3) Formation of the Cvt vesicle: Atg19 binds Atg8–PE, which drives the sequestration of the Cvt complex by
the double-membrane phagophore. (4) Fusion of the Cvt vesicle with the vacuole: After completion of the Cvt vesicle, the outer membrane
fuses with the vacuole, releasing the single membrane Cvt body into the lumen. The Cvt body is broken down by the Atg15 lipase, allowing
access to vacuolar hydrolases. Atg19 and Atg8 are degraded. The propeptide of prApe1 is removed and the enzyme becomes active.
analyze the gene products. After discovering the overlap with
the APG genes, we sent puriﬁed antisera against Ape1 to the
Ohsumi lab to be used in an electron microscopy analysis
by Misuzu Baba. I can still remember Yoshinori Ohsumi
crypticallytellingmeaboutsomestrikingandexcitingresults
that “could not be described” over the phone, but that
had to be seen in person. This resulted in a visit to Japan,
and the viewing of images that were indeed striking,
revealing that prApe1 import was morphologically similar to
autophagy (Figure 1)[ 21]. Much of the initial work on the
characterization of the Atg proteins was done in collabo-
ration with the Ohsumi lab [20, 22–27] and also with the
lab of Bill Dunn [22, 28–32], who was studying peroxisome
degradation in Pichia pastoris. Having established the his-
torical perspective, we now present some of the details of
those initial studies of the Cvt pathway, starting with the
characterizationofaminopeptidaseIimportbyamechanism
that is independent of the secretory pathway, identiﬁcation
of the vacuolar targeting domain, the isolation of mutants
defective in prApe1 delivery to the vacuole, and concluding
with the genetic and morphological studies that revealed the
overlap with autophagy.
2. The Transport of prApe1 to the Vacuole Is
Mediatedby theCvtPathway
Ape1 was initially characterized as a vacuolar enzyme that
hydrolyzes leucine peptides (hence the original nomencla-
ture leucine aminopeptidase, or LAP, which is unfortunately
confusing because LAPI is encoded by the LAP4 gene,
whereasLAPIVis encodedbyLAP2,et c.)[33].Thehydrolase
is synthesized as an inactive zymogen containing a propep-
tide that may sterically block its active site; it is processed to
its mature form in the vacuole by proteinase B in a PEP4-
dependent manner [34]. As mentioned above, published
data suggested that the Ape1 precursor was transported
through part of the secretory pathway, because it was char-
acterized as a glycoprotein [11]. However, a detailed charac-
terization of prApe1 biosynthesis suggested that its delivery
to the vacuole was independent of the secretory pathway:
(1) prApe1 lacks a signal sequence for transport into the
ER, and it is not glycosylated; (2) the half-life of processing
(i.e., removal of the propeptide in the vacuole) of prApe1
is substantially longer (∼30min) than that of Prc1 or Pep4
(∼6min), both of which are transported to the vacuole via
part of the secretory pathway; (3) vacuolar import of prApe1
is relatively unaﬀected by sec mutants [13].
The obvious question then became, how does prApe1
target to and enter the vacuole? A series of biochemical
analyses were performed to address this issue. After it is syn-
thesized as a 61-kDa protein in the cytosol, prApe1 is prote-
olytically processed to a mature 50-kDa form in the vacuole.
The prApe1 propeptide plays an essential role in the trans-
port process [35]. A detailed mutagenesis analysis carried
out by Mike Oda revealed that the ﬁrst amphipathic α-he-
lix in the propeptide is critical for the vacuolar targeting4 International Journal of Cell Biology
oftheenzyme.Deletionoftheprecursorregionormutations
that aﬀect the ﬁrst α-helical region inhibit its binding to the
membrane fraction and prevent subsequent vacuolar deliv-
ery and processing. Further analysis by John Kim revealed
that prApe1 is assembled as a dodecamer (∼669kDa) in the
cytoplasm prior to vacuolar delivery, which argued against
direct translocation across the vacuole limiting membrane
[36]. The propeptide of prApe1 is not required for its
oligomerization. A pulse chase analysis showed that the
oligomeric assembly and the subsequent membrane associ-
ation are very rapid events with a half-life of ∼3min. These
results suggested that the long half-life of prApe1 transport
may be due to the rate limiting step of the import of the
dodecamericenzymeintothevacuolelumenafteritsbinding
to membrane.
3.The Cvt andAutophagy PathwaysShare
t h eS am eM ac h in e ry
The oligomerization of prApe1 and the slow kinetics of im-
port into the vacuole argued against transport through the
secretorypathway.Tounderstandthemechanismofvacuolar
delivery, a detailed biochemical and genetic analysis was car-
ried out in S. cerevisiae, which revealed that autophagy and
the Cvt pathway largely share the same machinery for dou-
ble-membrane vesicle formation [16, 19, 20, 27]. A genetic
screen to analyze the Cvt pathway was carried out by moni-
toring the accumulation of prApe1 as described in Section 1.
From the initial screen, ﬁve cvt mutants (cvt2/atg7, cvt3, cvt5/
atg8, cvt6 and cvt7/atg9) were isolated, which showed a
complete block in prApe1 processing, but were not defective
in the maturation of the precursor form of Prc1 or Pep4
[16]. Most of these mutants also showed a defect in nonse-
lective autophagy [19, 20]. Just prior to the isolation of the
cvt mutants, Michael Thumm in Dieter Wolf’s lab isolated
as e r i e so faut mutants, based on defects in the degradation
of the fatty acid synthase. The aut mutants including aut3
(cvt10/atg1), aut5 (cvt17/atg15), aut7 (cvt5/atg8),a n daut9
(cvt7/atg9) also displayed a signiﬁcant block in the matu-
ration of prApe1, providing genetic evidence for a role of
theseproteinsinboththeCvtpathwayandautophagy[19].A
similar analysis of the apg mutants from Yoshinori Ohsumi’s
lab also revealed an extensive overlap [20]. Subsequently, all
of the ATG genes, except ATG11, ATG17, ATG19, ATG22,
ATG29,a n dATG31 were found to be required for both path-
ways. In 2003, the nomenclature for these CVT and APG/
AUT genes was uniﬁed as “ATG” for “autophagy related”
[37].
4.PrecursorAminopeptidaseIIsImportedby
aVesicularMechanism
The genetic overlap between the cvt and apg/aut mutants
gave rise to the idea of a vesicle-mediated mechanism for
prApe1 import. Indeed, electron microscopy analyses per-
formed by Misuzu Baba revealed that the prApe1 dode-
camers further assembled into a large complex composed
of multiple dodecamers (called an Ape1 complex), and that
in the cytoplasm this complex is surrounded by a double
membrane-bound structure, followed by fusion with the
vacuolar membrane [21], similar to what was observed in
bulk autophagy [38]. This result demonstrated the use of
an autophagy-like mechanism for the Cvt pathway. How-
ever, the double membrane structure enwrapping the Ape1
complex (termed a Cvt vesicle) is ∼150-nm in diameter, in
contrast with that of the autophagosome, which is 300–
900nm. In addition, the Cvt vesicle, in contrast to the au-
tophagosome, excludes bulk cytoplasm. Furthermore, while
autophagy is induced under starvation conditions, the Cvt
pathway occurs constitutively in growing conditions. Finally,
as we mentioned above, the Cvt pathway is a selective,
biosynthetic pathway, whereas autophagy is generally non-
selective and is degradative. How then could we explain
the apparent overlap in the import machinery? Importantly,
when cells are subjected to starvation, the Cvt complex is
sequestered within a larger autophagosome [38], although
the kinetics for import are essentially the same as during
vegetative growth. Thus, while the biosynthetic Cvt pathway
can be distinguished from autophagy, the Ape1 complex can
betakenupbyautophagosomesunderstarvationconditions,
again suggesting that the Cvt pathway and autophagy utilize
much of the same machinery.
In S. cerevisiae, the biogenesis and the vacuolar transport
of both autophagosomes and Cvt vesicles include the fol-
lowing steps: (1) membrane from various sources generates
vesicles containing Atg9 (see below) as a critical integral
membrane protein, and these vesicles form into tubulovesic-
ular clusters in a SNARE-dependent manner; (2) one or
more clusters contribute to the formation of a perivacuolar
phagophore assembly site (PAS), which is considered to be
a foundation/nucleation site that (3) leads to formation of
the phagophore, the initial sequestering compartment; (4)
two ubiquitin-like protein conjugation systems including
Atg8 and its conjugation to phosphatidylethanolamine (PE)
contribute to the formation and elongation of the phago-
phore to generate the double-membrane Cvt vesicle and
autophagosome; (5) the completed vesicles dock and fuse
with the vacuole, releasing the inner vesicle into the lumen
where the single-membrane structures are referred to as Cvt
or autophagic bodies.
Both autophagosomes and Cvt vesicles are said to be
formed de novo, to emphasize the fact that their generation
occurs by a mechanism that is distinct from that used in
the budding of transient transport vesicles in the secretory
pathway. Although the details of sequestering vesicle bio-
genesis are still not clear, almost all of the Atg proteins are
localized at least transiently to the PAS [39]. Atg9, which is
the sole integral membrane protein in yeast that is essential
for Cvt vesicle and autophagosome formation, is relatively
unique in that it is localized at multiple sites including the
PAS. The population of Atg9 at the non-PAS sites (Atg9
reservoirs) corresponds to the tubulovesicular clusters and is
proposedtotraﬃcbetweenthesesitesandthePAS,providing
membrane for phagophore expansion. The function of most
of the Atg proteins is still not known. For example, Atg8–
PE participates in cargo recognition during selective types of
autophagy and is also involved in determining the size of theInternational Journal of Cell Biology 5
autophagosome [40],butthedetailsof thesemechanisms are
not known.
5. Discovery of the Cvt-SpeciﬁcGenes
As mentioned above, not all of the cvt and apg/aut mutants
displayed an overlap; some mutants were defective only in
autophagy or the Cvt pathway, but not both. For example,
the atg11 mutant shows a complete block in the maturation
of prApe1, but is essentially normal for autophagy [19, 23].
These results suggested that the Cvt pathway and autophagy
share most of the same machinery, but that they also need
some molecules that are speciﬁc for each pathway. One
of the fundamental diﬀerences between the Cvt pathway
and autophagy concerns their temporal and physiological
activity. The Cvt pathway is active during vegetative growth,
consistent with its role as a biosynthetic traﬃcking route. In
contrast, autophagy is induced under starvation conditions,
where it can break down cellular macromolecules to supply
building blocks and energy. A complex of proteins including
Atg13, which is required both for the Cvt pathway and
autophagy, appears to be partly responsible for switching
thesepathwaysinresponsetochangesintheenvironment.In
starvation conditions, Atg13 interacts with the Atg1 complex
including Atg17, Atg29, and Atg31 to induce autophagy
[22, 41–43]. Under vegetative conditions, Atg13 may have a
lower aﬃnity for Atg1, a condition that may promote the Cvt
pathway. Atg13 is regulated by its phosphorylation status in a
TORC1-dependent manner; Atg13 is highly phosphorylated
in growing conditions but dephosphorylated in starvation
conditions [41, 44].
Another characteristic of the Cvt pathway is the speci-
ﬁcity for its cargo, whereas macroautophagy is a nonselective
process, suggesting that the Cvt pathway requires a receptor,
which recognizes the substrate. In this case, the substrate
corresponds to the cargo of the Cvt vesicles, which is
comprised primarily of the Ape1 complex. A systematic
yeast two-hybrid screen in S. cerevisiae was performed and
the gene product of YOL082W was found as a potential
interacting protein with prApe1 [45]. Biochemical analysis
demonstrated that YOL082W encodes a protein that func-
tions as a receptor for the targeting of prApe1 by the Cvt
pathway, and the gene was renamed CVT19 [46, 47]a n d
later ATG19 [37]. In atg19Δ cells, the precursor form of
Ape1 accumulates in the cytoplasm in both nutrient rich
and starvation conditions, suggesting that Atg19 is necessary
for the targeting of prApe1 both by the Cvt pathway and
autophagy. An important point in this regard is that import
of prApe1 by autophagy is still a selective process that utilizes
a receptor protein; this explains why the kinetics of import
are the same as for the Cvt pathway and are much faster than
would be expected for bulk uptake of cytoplasm.
An immunoprecipitation analysis showed that Atg19
physically interacts with the propeptide of prApe1, and the
coiled-coil domain of Atg19 mediates this interaction [48].
Atg19 localizes at the PAS with the Ape1 complex [49];
the combination of the Ape1 complex bound to Atg19 is
referred to as the Cvt complex. In atg19Δ cells, GFP-Ape1
forms a dodecamer, but it does not localize at the PAS. The
kinetics of the maturation of prApe1 and the degradation
of Atg19 are quite similar. Together with the localization
data, these ﬁndings suggest that Atg19 is delivered to the
vacuole by the Cvt pathway along with the precursor Ape1
dodecamer. Interestingly, deletion of APE1 results in a
dispersed Atg19 distribution, and Atg19 does not localize to
the PAS in ape1Δ cells, suggesting that the Ape1 complex
itself is required for concentrating its soluble receptor at this
site. Further analyses revealed that Atg19-prApe1 movement
to the PAS is dependent on Atg11, which we now know
acts as an adaptor or scaﬀold protein for selective autophagy
pathways, such as the Cvt pathway, and the selective
autophagic degradation of peroxisomes and mitochondria
(termed pexophagy and mitophagy, resp.) [22, 50]. Atg11
may mediate the transport of Atg9 to the PAS for selective
autophagyduringvegetativegrowth[51],whereasAtg17may
carry out this role for bulk autophagy during starvation.
Atg11 has certain characteristics of a scaﬀold protein in that
it interacts with several Atg proteins, including Atg1, Atg9,
Atg17, Atg19, Atg20, and itself [51, 52].
In the Cvt pathway, Atg19 binds the prApe1 propeptide
independent of any other Atg proteins. Atg11 can then
interact with Atg19, allowing movement of the cargo to the
PAS. Once at the PAS, Atg19 also interacts with Atg8–PE; it
is not known if both Atg8 and Atg11 bind Atg19 at the same
time, as their binding sites are distinct, but very close to each
other. Thus, Atg19 is a receptor that is responsible for
recognizing the prApe1 dodecamer to target it to the PAS
due to its interaction with Atg11. Furthermore, Atg19 leads
to the incorporation of the Cvt complex into a double-
membrane vesicle (i.e., a Cvt vesicle or autophagosome) via
its interaction with Atg8 [48]. In the absence of other Atg
proteins such as Atg1, Cvt vesicles, and autophagosomes
do not form; however, the Cvt complex is still targeted to
the PAS, suggesting that Atg19 transport of prApe1 to the
PAS occurs independent of the vesicle formation steps. Atg19
is both ubiquitinated and deubiquitinated in vivo, and these
modiﬁcations of Atg19 are required for the eﬃcient traf-
ﬁcking of prApe1 via the Cvt pathway [53]. Atg19 interacts
with the deubiquitinating enzyme Ubp3, and the deletion
of UBP3 leads to decreased targeting of prApe1. Further-
more, the mutation on the ubiquitin acceptor site, Lys213
and Lys216 of Atg19, reduces the interaction of Atg19 with
prApe1. Thus, the ubiquitination and deubiquitination of
Atg19 are likely to play a structural or mechanistic role in the
normal progression of the Cvt pathway, instead of serving as
a degradation signal for the proteasome.
As described above, many of the yeast Atg proteins
responsible for the Cvt pathway and autophagy have been
identiﬁed, and the general mechanism involved in these
processeshasbeenexploredthroughgeneticandbiochemical
approaches. Nevertheless, the molecular mechanism under-
lying nucleation of the sequestering phagophore remains
largely unknown. Many processes involving membrane rear-
rangement and movement, such as endocytosis or mem-
brane ruﬄing, require the cytoskeleton. The actin cytoskele-
tonis requiredfor the selective Cvt pathway, butnot for non-
selective autophagy in yeast [54]. Actin plays a role in
traﬃcking of Atg9 to the PAS and recruitment of the Cvt6 International Journal of Cell Biology
cargo in growing conditions. Further studies identiﬁed
actin-related proteins, including components of the Arp2/3
complex,asplayingaroleinthetransportofAtg9forspeciﬁc
types of autophagy [55]. The Arp2 protein itself interacts
with Atg9 and regulates the dynamics of Atg9 movement.
Thus, the Arp2/3 complex may allow Atg9, along with its
associated membrane, to move in a directed fashion to the
PASalongactincables.Thespeciﬁcautophagyfactorssuchas
Atg19 and Atg11, and perhaps other molecular components,
may serve as adaptors between the Cvt cargo and the actin
cytoskeleton.
6. Discovery of Other Cvt Cargo, Ams1
andApe4
Prior to the analysis of the Cvt pathway, Ams1 was shown
to enter the vacuole independent of the secretory pathway
[56], although the mechanism of import was unclear. We
found that Ams1 is another hydrolase targeted to the vacuole
by the Cvt pathway [57] ,a si t sd e l i v e r yi sb l o c k e di ncvt
(atg) mutants. Similar to prApe1, Ams1 forms oligomers
composed of 4 to 6 of the 122-kDa species in the cytosol, and
theoligomericstateismaintainedduringtheimportprocess.
Ams1 transport is also mediated by Atg19 [47] and its
binding site is distinct from that used by prApe1 [48]. Thus,
Ams1 is part of a prApe1-Atg19-Ams1 Cvt complex. In
ape1Δ cells, the Ams1-Atg19 interaction still occurs, but this
complex is dispersed in the cytosol, whereas deletion of
AMS1 does not aﬀect the transport of the prApe1-Atg19
complex. These results indicate that Ams1, which is synthe-
sized at a level that is substantially lower than prApe1, might
exploit the prApe1-Atg19 import system to achieve its own
eﬃcient transport to the vacuole.
Recently, it was shown that Ams1 is delivered to the vac-
uole in an Atg19-independent manner under starvation con-
ditions[58].Duringautophagy,Atg34(Yol083w),ahomolog
of Atg19, functions as a receptor for Ams1. In atg19Δ
cells, Ams1 targeting is disrupted in nutrient-rich conditions
[47, 48]. However, Ams1 is eﬃciently transported into the
vacuole under starvation conditions by autophagy even in
atg19Δ cells. A genome-wide yeast two-hybrid screen sug-
gested that Yol083w is an Ams1 interacting protein [45], and
Atg34 indeed physically interacts with Ams1 [58]. Similar to
Atg19, Atg34 binds Atg8 and Atg11 using distinct domains,
and these interactions are essential for its function in tar-
geting Ams1 into an autophagosome; an Atg34 mutant that
lacks its Atg8 interacting motif forms a complex with Ams1,
but shows a defect in sequestration into autophagosomes.
Importantly, the transport of Ams1 mediated by Atg34 in
starvation conditions is prApe1 independent, unlike that
mediated by Atg19 in growing conditions.
Also recently, aspartyl aminopeptidase (Yhr113w/Ape4)
was found to be a third Cvt cargo protein [59]. Yeast two-
hybrid analyses suggested that Ape4 can associate with Atg19
and prApe1 [60]. Unlike prApe1, Ape4 does not possess a
propeptide region and it does not self-assemble into aggre-
gates [59]; however, it still binds to Atg19. An immunopre-
cipitation analysis with truncated versions of Atg19 revealed
that the three identiﬁed Cvt cargo components, prApe1,
Ams1, and Ape4, associate with Atg19 by binding to distinct
sites. GFP-Ape4 colocalizes with RFP-Ape1 at the PAS in
growing conditions, and this localization is dependent on
Atg19. Notably, Ape4 transport to the vacuole by the Cvt
pathway is signiﬁcantly decreased in ape1Δ cells, suggesting
that Ape4 relies on the prApe1-Atg19 complex for its
targeting,similartoAms1invegetativeconditions.Inatg11Δ
cells, Ape4 can colocalize with prApe1, but it does not
localize at the PAS.
7. Conclusions
An intriguing question has been why yeast cells have utilized
the Cvt pathway to import a resident vacuolar hydrolase. In
higher eukaryotes, there is no evidence for a Cvt pathway,
and the ATG genes speciﬁcally involved in this pathway
are not conserved; in contrast, those genes that are also
needed for autophagy are highly conserved [61]. However,
selective types of autophagy clearly take place in higher
eukaryotes,includingmitophagyandpexophagy.Themolec-
ular machinery involved in these processes in mammalian
cells has not been completely elucidated, but it is likely that
the general mechanism is conserved. For example, receptors
such as BNIP3L and BNIP3 function as receptors in mam-
malian mitophagy, whereas Atg32 carries out this function
in yeast; BNIP3L and BNIP3 are not homologs of Atg32,
but they are functional counterparts, supporting the concept
of mechanistic conservation. Furthermore, most of the
machinery for the Cvt pathway is also used for pexophagy
and mitophagy, which, as noted above, take place in higher
eukaryotes. This means that with regard to the Atg proteins,
theapparentabsenceoftheCvtpathwayinmammalsmaybe
viewed as a deﬁciency in the speciﬁc receptor Atg19, rather
than a major diﬀerence between yeast and other eukaryotes.
Returning to the initial question regarding the origin
of the Cvt pathway, one possibility is that the oligomeric
structure of prApe1 or Ams1 is critical for stability and/or
function. The size of the oligomeric form of these hydrolases
would prevent translocation through the ER translocon,
necessitating a vesicle-mediated import process. Also, Ams1
does not appear to be synthesized as a zymogen. Thus, it
would be problematic for this hydrolase to traverse the secre-
torypathwayalongwithothernewlysynthesizedglycosylated
proteins. These vacuolar hydrolases are likely required in
large amounts when the cell is starved or when aggregated
proteins or damaged organelles accumulate, and the synthe-
sis of most vacuolar hydrolases increases substantially during
starvation. Under these conditions, the eﬃcient transport of
these hydrolases as oligomers by means of a vesicle-mediated
mechanism such as autophagy would be extremely eﬃcient.
Itwouldseemreasonableforthecelltomodifytheautophagy
pathway very slightly with the addition of a small number
of speciﬁcity components to take advantage of the existing
autophagy machinery and allow it to be used for various
types of selective sequestration processes.
Acknowledgment
This work was supported by NIH public health service Grant
GM53396 to D. J. Klionsky.International Journal of Cell Biology 7
References
[1] V. A. Bankaitis, L. M. Johnson, and S. D. Emr, “Isolation of
yeast mutants defective in protein targeting to the vacuole,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 83, no. 23, pp. 9075–9079, 1986.
[2] J. H. Rothman and T. H. Stevens, “Protein sorting in yeast:
mutants defective in vacuole biogenesis mislocalize vacuolar
proteins into the late secretory pathway,” Cell, vol. 47, no. 6,
pp. 1041–1051, 1986.
[3] Y. H. Chang and J. A. Smith, “Molecular cloning and sequenc-
ing of genomic DNA encoding aminopeptidase I from Sac-
charomyces cerevisiae,” The Journal of Biological Chemistry, vol.
264, no. 12, pp. 6979–6983, 1989.
[4] R. Cueva, N. Garcia-Alvarez, and P. Suarez-Rendueles, “Yeast
vacuolar aminopeptidase yscI. Isolation and regulation of the
APE1 (LAP4) structural gene,” FEBS Letters, vol. 259, no. 1,
pp. 125–129, 1989.
[5] G. Ammerer, C. P. Hunter, J. H. Rothman, G. C. Saari, L. A.
V a l l s ,a n dT .H .S t e v e n s ,“ PEP4 gene of Saccharomyces cere-
visiae encodes proteinase A, a vacuolar enzyme required for
processing of vacuolar precursors,” Molecular and Cellular
Biology, vol. 6, no. 7, pp. 2490–2499, 1986.
[6] C. A. Woolford, L. B. Daniels, F. J. Park, E. W. Jones, J. N. Van
Arsdell, and M. A. Innis, “The PEP4 gene encodes an aspartyl
protease implicated in the posttranslational regulation of
Saccharomyces cerevisiae vacuolar hydrolases,” Molecular and
Cellular Biology, vol. 6, no. 7, pp. 2500–2510, 1986.
[ 7 ]L .A .V a l l s ,C .P .H u n t e r ,J .H .R o t h m a n ,a n dT .H .S t e v e n s ,
“Protein sorting in yeast: the localization determinant of yeast
vacuolar carboxypeptidase Y resides in the propeptide,” Cell,
vol. 48, no. 5, pp. 887–897, 1987.
[8] Y. Kaneko. Y., N. Hayashi, A. Toh-e, I. Banno, and Y. Oshima,
“StructuralcharacteristicsofthePHO8geneencodingrepress-
ible alkaline phosphatase in Saccharomyces cerevisiae,” Gene,
vol. 58, no. 1, pp. 137–148, 1987.
[ 9 ]C .M .M o e h l e ,R .T i z a r d ,S .K .L e m m o n ,J .S m a r t ,a n dE .W .
Jones, “Protease B of the lysosomelike vacuole of the yeast
Saccharomycescerevisiaeishomologoustothesubtilisinfamily
of serine proteases,” Molecular and Cellular Biology, vol. 7, no.
12, pp. 4390–4399, 1987.
[10] M. J. Kuranda and P. W. Robbins, “Cloning and heterologous
expressionofglycosidasegenesfromSaccharomycescerevisiae,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 84, no. 9, pp. 2585–2589, 1987.
[11] G. Metz and K. H. Roehm, “Yeast aminopeptidase I. Chemical
composition and catalytic properties,” Biochimica et Biophys-
ica Acta, vol. 429, no. 3, pp. 933–949, 1976.
[ 1 2 ]B .D i s t e l ,E .J .M .A l ,H .F .T a b a k ,a n dE .W .J o n e s ,“ S y n t h e s i s
and maturation of the yeast vacuolar enzymes carboxypepti-
dase Y and aminopeptidase I,” Biochimica et Biophysica Acta,
vol. 741, no. 1, pp. 128–135, 1983.
[13] D. J. Klionsky, R. Cueva, and D. S. Yaver, “Aminopeptidase I
of Saccharomycescerevisiae islocalized tothevacuole indepen-
dent of the secretory pathway,” The Journal of Cell Biology, vol.
119, no. 2, pp. 287–300, 1992.
[14] K. Takeshige, M. Baba, S. Tsuboi, T. Noda, and Y. Ohsumi,
“Autophagy in yeast demonstrated with proteinase-deﬁcient
mutants and conditions for its induction,” The Journal of Cell
Biology, vol. 119, no. 2, pp. 301–312, 1992.
[15] J. F. Dice, H. L. Chiang, E. P. Spencer, and J. M. Backer, “Reg-
ulation of catabolism of microinjected ribonuclease A. Identi-
ﬁcation of residues 7–11 as the essential pentapeptide,” The
Journal of Biological Chemistry, vol. 261, no. 15, pp. 6853–
6859, 1986.
[16] T. M. Harding, K. A. Morano, S. V. Scott, and D. J. Klionsky,
“Isolation and characterization of yeast mutants in the cyto-
plasm to vacuole protein targeting pathway,” The Journal of
Cell Biology, vol. 131, no. 3, pp. 591–602, 1995.
[17] M. Tsukada and Y. Ohsumi, “Isolation and characterization
of autophagy-defective mutants of Saccharomyces cerevisiae,”
FEBS Letters, vol. 333, no. 1-2, pp. 169–174, 1993.
[18] M. Thumm, R. Egner, B. Koch et al., “Isolation of autophago-
cytosis mutants of Saccharomyces cerevisiae,” FEBS Letters, vol.
349, no. 2, pp. 275–280, 1994.
[19] T. M. Harding, A. Hefner-Gravink, M. Thumm, and D. J.
Klionsky, “Genetic and phenotypic overlap between auto-
phagy and the cytoplasm to vacuole protein targeting path-
way,” The Journal of Biological Chemistry, vol. 271, no. 30, pp.
17621–17624, 1996.
[20] S. V. Scott, A. Hefner-Gravink, K. A. Morano, T. Noda, Y.
Ohsumi, and D. J. Klionsky, “Cytoplasm-to-vacuole targeting
and autophagy employ the same machinery to deliver proteins
to the yeast vacuole,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 93, no. 22, pp.
12304–12308, 1996.
[21] M. Baba, M. Osumi, S. V. Scott, D. J. Klionsky, and Y. Ohsumi,
“Two distinct pathways for targeting proteins from the cyto-
plasm to the vacuole/lysosome,” The Journal of Cell Biology,
vol. 139, no. 7, pp. 1687–1695, 1997.
[22] J. Kim, Y. Kamada, P. E. Stromhaug et al., “Cvt9/Gsa9 func-
tions in sequestering selective cytosolic cargo destined for the
vacuole,” The Journal of Cell Biology, vol. 153, no. 2, pp. 381–
396, 2001.
[23] S. V. Scott, D. C. Nice, J. J. Nau et al., “Apg13p and Vac8p are
part of a complex of phosphoproteins that are required for
cytoplasm to vacuole targeting,” The Journal of Biological
Chemistry, vol. 275, no. 33, pp. 25840–25849, 2000.
[24] M. D. George, M. Baba, S. V. Scott et al., “Apg5p functions in
the sequestration step in the cytoplasm-to-vacuole targeting
and macroautophagy pathways,” Molecular Biology of the Cell,
vol. 11, no. 3, pp. 969–982, 2000.
[25] T. Noda, J. Kim, W.-P. Huang et al., “Apg9p/Cvt7p is an inte-
gral membrane protein required for transport vesicle forma-
tion in the Cvt and autophagy pathways,” The Journal of Cell
Biology, vol. 148, no. 3, pp. 465–479, 2000.
[26] N. Mizushima, T. Noda, T. Yoshimori et al., “A protein con-
jugation system essential for autophagy,” Nature, vol. 395, no.
6700, pp. 395–398, 1998.
[27] S. V. Scott, M. Baba, Y. Ohsumi, and D. J. Klionsky, “Ami-
nopeptidase I is targeted to the vacuole by a nonclassical
vesicular mechanism,” The Journal of Cell Biology, vol. 138, no.
1, pp. 37–44, 1997.
[28] K. A. Tucker, F. Reggiori, W. A. Dunn, and D. J. Klionsky,
“Atg23 is essential for the cytoplasm to vacuole targeting path-
way and eﬃcient autophagy but not pexophagy,” The Journal
of Biological Chemistry, vol. 278, no. 48, pp. 48445–48452,
2003.
[29] H. Abeliovich, C. Zhang, W. A. Dunn, K. M. Shokat, and D.
J. Klionsky, “Chemical genetic analysis of Apg1 reveals a non-
kinase role in the induction of autophagy,” Molecular Biology
of the Cell, vol. 14, no. 2, pp. 477–490, 2003.
[ 3 0 ] J .G u a n ,P .E .S t r o m h a u g ,M .D .G e o r g ee ta l . ,“ C v t 1 8 / G s a 1 2i s
required for cytoplasm-to-vacuole transport, pexophagy, and
autophagy in Saccharomyces cerevisiae and Pichia pastoris,”
Molecular Biology of the Cell, vol. 12, no. 12, pp. 3821–3838,
2001.8 International Journal of Cell Biology
[31] C.-W. Wang, J. Kim, W.-P. Huang et al., “Apg2 is a novel pro-
tein required for the cytoplasm to vacuole targeting, auto-
phagy, and pexophagy pathways,” The Journal of Biological
Chemistry, vol. 276, no. 32, pp. 30442–30451, 2001.
[32] H.A belio vic h,W .A.DunnJr .,J .K im,andD .J .Klionsky ,“Dis-
section of autophagosome biogenesis into distinct nucleation
and expansion steps,” The Journal of Cell Biology, vol. 151, no.
5, pp. 1025–1034, 2000.
[33] J.FreyandK.H.Roehm,“Subcellularlocalizationandlevelsof
aminopeptidases and dipeptidase in Saccharomyces cerevisiae,”
Biochimica et Biophysica Acta, vol. 527, no. 1, pp. 31–41, 1978.
[34] R. J. Trumbly and G. Bradley, “Isolation and characterization
of aminopeptidase mutants of Saccharomyces cerevisiae,” Jour-
nal of Bacteriology, vol. 156, no. 1, pp. 36–48, 1983.
[35] M.N.Oda,S.V.Scott,A.Hefner-Gravink,A.D.Caﬀarelli,and
D. J. Klionsky, “Identiﬁcation of a cytoplasm to vacuole tar-
geting determinant in aminopeptidase I,” The Journal of Cell
Biology, vol. 132, no. 6, pp. 999–1010, 1996.
[36] J.Kim,S.V.Scott,M.N.Oda,andD.J.Klionsky,“Transportof
a large oligomeric protein by the cytoplasm to vacuole protein
targeting pathway,” The Journal of Cell Biology, vol. 137, no. 3,
pp. 609–618, 1997.
[37] D. J. Klionsky, J. M. Cregg, W. A. Dunn et al., “A uniﬁed no-
menclature for yeast autophagy-related genes,” Developmental
Cell, vol. 5, no. 4, pp. 539–545, 2003.
[38] M. Baba, K. Takeshige, N. Baba, and Y. Ohsumi, “Ultrastruc-
tural analysis of the autophagic process in yeast: detection of
autophagosomes and their characterization,” The Journal of
Cell Biology, vol. 124, no. 6, pp. 903–913, 1994.
[39] K.Suzuki,T.Kirisako,Y.Kamada,N.Mizushima,T.Noda,and
Y. Ohsumi, “The pre-autophagosomal structure organized by
concerted functions of APG genes is essential for autophago-
some formation,” The EMBO Journal, vol. 20, no. 21, pp.
5971–5981, 2001.
[40] Z. Xie, U. Nair, and D. J. Klionsky, “Atg8 controls phagophore
expansion during autophagosome formation,” Molecular Biol-
ogy of the Cell, vol. 19, no. 8, pp. 3290–3298, 2008.
[41] Y. Kamada, T. Funakoshi, T. Shintani, K. Nagano, M. Ohsumi,
and Y. Ohsumi, “Tor-mediated induction of autophagy via an
Apg1 protein kinase complex,” The Journal of Cell Biology, vol.
150, no. 6, pp. 1507–1513, 2000.
[42] T.Kawamata,Y.Kamada,K.Suzukietal.,“Characterizationof
anovelautophagy-speciﬁcgene,ATG29,” BiochemicalandBio-
physical Research Communications, vol. 338, no. 4, pp. 1884–
1889, 2005.
[ 4 3 ]Y .K a b e y a ,T .K a w a m a t a ,K .S u z u k i ,a n dY .O h s u m i ,“ C i s 1 /
Atg31 is required for autophagosome formation in Saccha-
romycescerevisiae,” BiochemicalandBiophysicalResearchCom-
munications, vol. 356, no. 2, pp. 405–410, 2007.
[44] Y. Kamada, K. I. Yoshino, C. Kondo et al., “Tor directly con-
trols the Atg1 kinase complex to regulate autophagy,” Molecu-
lar and Cellular Biology, vol. 30, no. 4, pp. 1049–1058, 2010.
[45] P. Uetz, L. Glot, G. Cagney et al., “A comprehensive analysis
of protein-protein interactions in Saccharomyces cerevisiae,”
Nature, vol. 403, no. 6770, pp. 623–627, 2000.
[46] R.Leber,E.Silles,I.V.Sandoval,andM.J.Maz´ on,“Yo1082p,a
novel CVT protein involved in the selective targeting of
aminopeptidase I to the yeast vacuole,” The Journal of Bio-
logical Chemistry, vol. 276, no. 31, pp. 29210–29217, 2001.
[47] S. V. Scott, J. Guan, M. U. Hutchins, J. Kim, and D. J. Klionsky,
“Cvt19 is a receptor for the cytoplasm-to-vacuole targeting
pathway,” Molecular Cell, vol. 7, no. 6, pp. 1131–1141, 2001.
[48] T. Shintani, W.-P. Huang, P. E. Stromhaug, and D. J. Klionsky,
“Mechanism of cargo selection in the cytoplasm to vacuole
targeting pathway,” Developmental Cell, vol. 3, no. 6, pp. 825–
837, 2002.
[49] J. Kim, W.-P. Huang, P. E. Stromhaug, and D. J. Klionsky,
“Convergence of multiple autophagy and cytoplasm to vac-
uole targeting components to a perivacuolar membrane com-
partment prior to de Novo vesicle formation,” The Journal of
Biological Chemistry, vol. 277, no. 1, pp. 763–773, 2002.
[50] T. Kanki and D. J. Klionsky, “Mitophagy in yeast occurs
through a selective mechanism,” The Journal of Biological
Chemistry, vol. 283, no. 47, pp. 32386–32393, 2008.
[51] C.He,H.Song,T.Yorimitsuetal.,“RecruitmentofAtg9tothe
preautophagosomalstructurebyAtg11isessentialforselective
autophagy in budding yeast,” The Journal of Cell Biology, vol.
175, no. 6, pp. 925–935, 2006.
[52] T. Yorimitsu and D. J. Klionsky, “Atg11 links cargo to the
vesicle-forming machinery in the cytoplasm to vacuole target-
ing pathway,” Molecular Biology of the Cell,v o l .1 6 ,n o .4 ,p p .
1593–1605, 2005.
[53] B. K. Baxter, H. Abeliovich, X. Zhang, A. G. Stirling, A. L.
Burlingame, and D. S. Goldfarb, “Atg19p ubiquitination and
the cytoplasm to vacuole traﬃcking pathway in yeast,” The
Journal of Biological Chemistry, vol. 280, no. 47, pp. 39067–
39076, 2005.
[54] F. Reggiori, I. Monastyrska, T. Shintani, and D. J. Klionsky,
“The actin cytoskeleton is required for selective types of auto-
phagy, but not nonspeciﬁc autophagy, in the yeast Saccha-
romyces cerevisiae,” Molecular Biology of the Cell, vol. 16, no.
12, pp. 5843–5856, 2005.
[55] I. Monastyrska, C. He, J. Geng, A. D. Hoppe, Z. Li, and D.
J. Klionsky, “Arp2 links autophagic machinery with the actin
cytoskeleton,” Molecular Biology of the Cell,v o l .1 9 ,n o .5 ,p p .
1962–1975, 2008.
[56] T. Yoshihisa and Y. Anraku, “A novel pathway of import of
α-mannosidase, a marker enzyme of vacuolar membrane, in
Saccharomyces cerevisiae,” The Journal of Biological Chemistry,
vol. 265, no. 36, pp. 22418–22425, 1990.
[57] M. U. Hutchins and D. J. Klionsky, “Vacuolar localization of
oligomeric α-mannosidase requires the cytoplasm to vacuole
targeting and autophagy pathway components in Saccha-
romyces cerevisiae,” The Journal of Biological Chemistry, vol.
276, no. 23, pp. 20491–20498, 2001.
[ 5 8 ] K .S u z u k i ,C .K o n d o ,M .M o ri m o t o ,a n dY .O h s u m i ,“ S e l e c t i v e
transport of α-mannosidase by autophagic pathways: identi-
ﬁcation of a novel receptor, Atg34p,” The Journal of Biological
Chemistry, vol. 285, no. 39, pp. 30019–30025, 2010.
[59] M. Yuga, K. Gomi, D. J. Klionsky, and T. Shintani, “Aspartyl
aminopeptidaseisimportedfromthecytoplasmtothevacuole
by selective autophagy in Saccharomyces cerevisiae,” The Jour-
nal of Biological Chemistry, vol. 286, no. 15, pp. 13704–13713,
2011.
[60] T. Ito, T. Chiba, R. Ozawa, M. Yoshida, M. Hattori, and Y.
Sakaki, “A comprehensive two-hybrid analysis to explore the
yeast protein interactome,” Proceedings of the National Acad-
emy of Sciences of the United States of America,v o l .9 8 ,n o .8 ,
pp. 4569–4574, 2001.
[61] W. H. Meijer, I. J. Van Der Klei, M. Veenhuis, and J. A. K. W.
Kiel, “ATG genes involved in non-selective autophagy are con-
served from yeast to man, but the selective Cvt and pexophagy
pathways also require organism-speciﬁc genes,” Autophagy,
vol. 3, no. 2, pp. 106–116, 2007.